At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 36 enrolled
Drug / intervention
turoctocog alfa pegoldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A
In Brief
A Phase 3 clinical trial evaluating turoctocog alfa pegol for Congenital Bleeding Disorder and Haemophilia A. Completed, enrolled 36 participants across 70 sites in 21 countries.
Detailed Summary
This trial is conducted globally. The aim of this trial is to evaluate the haemostatic effect of NNC 0129-0000-1003 during surgical procedures in subjects with haemophilia A.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCongenital Bleeding Disorder, Haemophilia A
CountriesAustralia, Brazil, Bulgaria, Croatia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Malaysia, Netherlands, Norway, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 2011
Enrollment StartAug 2012
Primary CompletionDec 2018
TodayJul 2026
First PostedDec 9, 2011
Enrollment StartAug 3, 2012
Primary CompletionDec 10, 2018
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 14.6 years ago
Interventions
turoctocog alfa pegoldrug
Bleeding preventive treatment administered i.v. before, during and after surgery. Individually adjusted doses.